Note: Descriptions are shown in the official language in which they were submitted.
CA 02227202 1998-O1-19
D E S C R I P T I O N
The invention relates to a transdermal therapeutic system
for delivering active substances to the human body via the
skin.
Transdermal therapeutic systems (TTS) have already been in-
troduced on the market for the therapeutic therapy of a
number of illnesses.
A disadvantage of the systems according to the prior art is
the insufficient skin permeability of many active sub-
stances, which permeability cannot be improved above a cer-
tain limit, the so-called "saturation flow", even through
numerous galenic measures taken in respect of the TTS de-
sign (use of multi-layered systems, use of control mem-
branes, variation of the active substance concentration,
modification of the base polymers, etc.). The statement
that the transdermal flow of an active substance from the
solid, finely dispersed phase can in principle not be in-
creased any further, even despite the use of more strongly
dissolving vehicles, can already be found in the works of
Higuchi, which are pathbreaking to this day (e. g. T. Higu-
chi: Physical Chemical Analysis of percutaneous absorptions
process from creams and ointments. J. Soc. Cosmetic Chem,
11, S. 85-97 (1960).
With a great number of active substances, however, there is
the possibility of adding a penetration enhancer, a so-
called "enhancer", to the TTS during its manufacture. Gen-
erally, these are llquld or volatile additives improving
the absorption properties of the human skin, thus enabling
a sufficiently high absorption of the active substance from
a relatively small TTS area. However, highly volatile en-
hancers, such as, for example, ethanol, wha.ch is used for
CA 02227202 1998-O1-19
2
the active substance estradiol, present problems due to the
strong softening of the adhesive layers of the TTS, thus
necessitating further space-consuming compartments in the
system, which renders the TTS unacceptably thick or its
surface area unacceptably large. Moreover, each additional
non-polymeric additive involves a risk of incompatibility
reactions on the skin, possibly also of sensitisation.
Through adding certain less volatile, but mostly also less
active, enhancers (e. g. glycerol esters, cyclic amides,
eucalyptol) it is possible to prepare matrix systems which
contain the active substance and the absorption-enhancing
components in one or more monolithic layers.
According to the prior art it is, however, not possible to
achieve a satisfactory therapy with such TTS if the en-
hancers are poorly skin-compatible or if the systems, due
to the flux through the skin being still too low, require
unacceptably large surface areas.
Another ;possibility of increasing the active substance flow
through the skin is to dissolve a greater amount of the ac-
tive substance in a molecular-disperse manner than corre-
sponds to the saturation solubility. With such oversatura-
tion of these systems, the rate of permeation through the
skin increases to the same extent. Since such states are
thermodynamically unstable, it is difficult to provide such
administration forms a.n a form which can be stored; a re-
crystallisation process of active substance particles takes
place whose onset and duration cannot be foreseen. This re-
crystallisation process results in the flow rate through
the skin. gradually falling to the saturation flow level,
thus causing a loss of a large part of the initially pres-
ent therapeutic activity, depending on the initial concen-
tration.
In a great number of cases where such recrystallisation oc-
curred it was observed that crystallisations have their
CA 02227202 1998-O1-19
3
origin not in the components of the TTS but in the abherent
layer.
Starting from the above-mentioned prior art it is the ob-
ject of the invention to provide a transdermal therapeutic
system which has a layered structure comprising a backing
layer and at least one active substance-containing matrix
layer and which is not subject to premature precipitation,
or only to inconsiderable premature precipitation, of the
active substance when stored in contact with a removable
protective layer which is pre-coated with an abherent.
According to the invention this object is achieved in that
the abherent has a lower diffusion coefficient for the ac-
tive substance used than the base materials used in the ma-
trix layer or in the matrix layers. This is achieved, in
particular, by using fluorine-containing polymers as compo-
nents of the abherent layer.
By means of serial investigations with different pairings
between ;single-layered and multilayered matrices as well as
with protective layers coated with different abherents, it
was surprisingly found that recrystallisation processes
regularly slow down or even do not occur at all if abher-
ents are selected which have a low diffusion coefficient.
Thus, in the sense of the invention, fluorine-containing
polymers are found particularly suitable, which, besides
the more common silicone-based abherents, are available on
the market in sufficient quality. A great variety of such
abherents is already available in prefabricated composites
with the protective sheet, the latter generally having a
greater thickness. The use of abherent-coated foils or
sheets is preferable to the use of full layers of the ab-
herent because it results in a reduction of the costs for
the, frequently expensive, abherent, or because advantages
CA 02227202 1998-O1-19
4
with regard to strength are achieved. However, in accor-
dance with the invention, it is also possible to provide
the protective layer including the abherent layer from one
uniform material.
The particularly preferred fluorocarbon polymers may con-
sist of polytetrafluoroethylene, perfluoroethylenepropylene
copolymers, perfluoroalkoxy copolymers, polychlorotri-
fluoroethylene, ethylene-tetrafluoroethylene copolymers,
ethylene-chlorotrifluoroethylene copolymers, polyvinylidene
fluoride or even polyvinyl fluoride, this enumeration not
being exhaustive but merely serving to illustrate a selec-
tion of possibilities.
Furthermore, the abherents may also consist of other sub-
stances that are poorly diffusible in comparison with the
matrix base material, such as, for instance, polyethylene,
polypropylene, polyvinylchloride or polyvinylidene chlo-
ride, provided they have sufficient parting properties.
Apart from the common acrylic-acid ester copolymers other
polymers may be used as base material, such as polyisobuty-
lene, po:lyvinylacetate and copolymers, synthetic rubber,
and silicones. If required, for example for achieving suf-
ficient adhesive power, mixtures of such and other polymers
with additives, e.g. resins, skin-compatible oil compo-
nents, fillers, etc., may be used, the base materials of
the matrix layer or matrix layers consisting for the most
part of water-insoluble skin-compatible polymers and of
resin components suitable for skin contact.
The effect according to the invention is, however, most ap-
parent if copolymers of dienes and styrene, polyisobutylene
or natural rubber are used, and derivatives of natural res-
ins or hydrocarbon resins are added as tackifiers.
CA 02227202 1998-O1-19
The advantage of the invention can be observed particularly
with active substances which are solid at the intended
storage temperature. Of these, the following are to be men-
tioned in particular:
centrally active substances such as, for example, amanta-
dine, benztropine, biperiden, bornaprine, trihexyphenidyl,
tranylcypromine, physostigmine, selegilin, doxepin,
maprotil:ine, imipramine, perphenazine, haloperidol, ben-
peridol, sulpiride, pimozide, methylphenidate, am-
phetamim:il, amphetamine, cocaine, oxazepam, alprazolam, di-
azepam, :lorazepam, buspirone, xanomeline, piracetam, ephe-
drine, norpseudoephedrine, fenproporex, fenfluramine,
OplOld analgesics such as morphine, heroine, tilidine, al-
fentanile, methadone, sufentanil, fentanyl,
peripherally active analgesics such as ketorolac, ketopro-
fene, indomethacin, acetylsalicylic acid, diclofenac,
t enoxi c aim,
anticoagulants such as warfarin, phenprocoumone, acetyl-
salicylic acid, acenocoumarol,
antihist.aminics such as pheniramine, chlorpheniramine, ter-
fenadine, trimetindene, prednisolone, bamipine, clemastin,
steroid :hormones, for example for post-menopausal, ana-
bolic, contraceptive or anti-inflammatory use, such as me-
droxyprogesterone, levonorgestrel, testosterone, methe-
nolone, :nandrolone, androsterone, cyproterone acetate, me-
droxyprogesterone acetate, lynoestrenol, norethisterone,
epimestrol, estriol, estrone, estradiol valerate, estradiol
propionate, norethisterone acetate, norgestrel, gestodene,
mestranol, estradiol, ethinylestradiol,
prostaglandins, such as gemeprost, dinoprostone, sulpros-
ton,
osteoprotective substances such as vitamins D3, raloxifene,
etidronic acid,
hypotensive substances such as enalapril, captopril, moxo-
nidine, clonidine, timolol, propanolol, bupranolol, bopin-
dolol, metoprolol, pindolol, mepindolol,
CA 02227202 1998-O1-19
6
sympathotonic substances such as etilefrine, ephedrine, mi-
dodrine,
antialle:rgics such as phenuramine, brompheniramine, ke-
totifen, terfenadine, dimethindene maleate, cyproheptadine,
local anaesthetics such as salbutamol, clenbuterol, tulo-
buterol, atropine scopolomine, fenoterol,
and many other active substances which are not mentioned
here in detail.
According to the invention, the diffusibility of the abher-
ent is to be lower than that of the base material of the
matrix layers. In the literature a number of methods for
determining the diffusion coefficient are described which
are derived from Fick's laws. Thus, it is, for example,
possible to examine layers of the abherent or of a matrix
base mat~srial which are preloaded with active substance, at
a determined temperature in a diffusion cell, in which the
released substance amount can be determined in dependence
on time. The process of determining the diffusion coeffi-
cient can be carried out, for example, according to Kokubo
et al., :Proceed. Intern. Symp. Control, Rel. Bioact. Mater.
17 (1990), pages 271 - 272. In the TTS according to the in-
vention, the resulting diffusion coefficient of the ab-
herent i.s to be smaller than the diffusion coefficient of
the matrix.
Fig. 1 illustrates, by way of example, a system according
to the invention, comprising backing layer (1), matrix (2),
abherent (abherent layer) (3) and protective layer (4). Ma-
trix (2) can also be multi-layered.
Example 1:
Preparation of a system according to the invention
2.0 g 17-8-estradiol semihydrate, micronised
CA 02227202 1998-O1-19
7
60.0 g Cariflex~ TR 1107 (styrene-isoprene-styrene block
copolymer)
120.0 g staybelite ester 5E (thermoplastic ester resin of
colophony derivatives)
20 g viscous paraffin
are stirred in a cylindrical glass vessel until a uniform
suspension results, and subsequently coated at a gap width
of 500 micrometers onto a 100-dun-thick polyester film pre-
coated with 2 g/ms silicone rubber. The coating is dried
dried at 25 °C, 50 °C, 80 °C and at 95 °C for 10
minutes at
each temperature. Immediately, a 15-dun-thick polyester film
is placed (laminated) under roll pressure onto the dried
layer, avoiding air bubbles.
By punch'_~ng with a wad punch, transdermal systems of 10 cmz
are obtained, which are packed in composite packageing ma-
terial of paper/aluminium foil/heat sealing layer, adding a
drying tablet containing 0.3 g calcium sulfate (which has
been previously predried at 180 °C).
Subsequently, 15-dun-thick polyester film is placed (lami-
nated) onto the still warm layer under roll pressure,
avoiding air bubbles.
By punch_'ing with a wad punch, transdermal systems of 20 cms
are obtained.
Example 2:
Comparison example to 1
2.0 g 17-8-estradiol semihydrate, micronised
60.0 g Cariflex~ TR 1107 (styrene-isoprene-styrene block
copolymer)
120.0 g staybelite ester 5E (thermoplastic ester resin of
colophony derivatives)
20 g viscous paraffin
CA 02227202 1998-O1-19
8
are stirred at room temperature in a cylindrical glass ves-
sel until a homogenous suspension is obtained, and subse-
quently coated at a gap width of 500 micrometers onto a
100-micrometer-thick polyester film (Scotchpak~ 1022)
which ha;s been pre-coated with fluoropolymer. The spread is
dried at 25 °C, 50 °C, 80 °C and at 95 °C for 10
minutes at
each temperature. Immediately, a 15-pm-thick polyester film
is placed (laminated) under roll pressure onto the dried
layer, avoiding air bubbles.
By punching with a wad punch, transdermal systems of 10 cms
are obtained, which are packed in composite packageing ma-
terial o:E paper/aluminium foil/heat sealing layer, adding a
drying tablet containing 0.3 g calcium sulfate (which has
been pre~~riously predried at 180 °C).
Subsequently, 15-dun-thick polyester film is placed (lami-
nated) under roll pressure onto the still warm layer,
avoiding air bubbles.
By punching with a wad punch, transdermal systems of 20 cms
are obtained.
